 Connection
Erin Harvey to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Erin Harvey has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.739 |
|
|
|
-
Harvey ES, Hamada Y, Hiles SA, Langton D, Thomas D, McDonald VM, Bardin P, Peters M, Reynolds PN, Upham JW, Blakey J, Bowler S, Chien J, Chung LP, Farah CS, Gillman A, Harrington J, Hew M, Jenkins C, Katelaris CH, Katsoulotos GP, Kritikos V, Lee J, Radhakrishna N, Sivakumaran P, Wark PAB, Gibson PG. Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry. Respir Med. 2025 Nov; 248:108340.
Score: 0.649
-
Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020 05; 55(5).
Score: 0.450
-
Hamada Y, Thomas D, McDonald VM, Harvey ES, Fricker M, Gillman A, Hew M, Kritikos V, Upham JW, Gibson PG. Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab. Ann Allergy Asthma Immunol. 2025 Nov; 135(5):537-546.e12.
Score: 0.160
-
Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Gibson PG. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2025 Jan; 65(1).
Score: 0.156
-
Hamada Y, Gibson PG, Harvey ES, Stevens S, Lewthwaite H, Fricker M, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Thomas D. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2025 Feb; 13(2):333-342.e9.
Score: 0.153
-
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, Gillman A, Hew M, Hodge S, James A, Jenkins C, Katelaris CH, Katsoulotos GP, Langton D, Lee J, Marks G, Peters M, Radhakrishna N, Reynolds PN, Rimmer J, Sivakumaran P, Upham JW, Wark P, Yang IA, Gibson PG. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024 02; 79(2):384-392.
Score: 0.141
-
Thomas D, Harvey ES, McDonald VM, Stevens S, Upham JW, Katelaris CH, Kritikos V, Gillman A, Harrington J, Hew M, Bardin P, Peters M, Reynolds PN, Langton D, Baraket M, Bowden JJ, Bowler S, Chien J, Chung LP, Farah CS, Grainge C, Jenkins C, Katsoulotos GP, Lee J, Radhakrishna N, Reddel HK, Rimmer J, Sivakumaran P, Wark PAB, Gibson PG. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. J Allergy Clin Immunol Pract. 2021 07; 9(7):2715-2724.e5.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|